Case-Based Learning on Cognitive Decline With Mixed Neurodegenerative and Vascular Features

Abstract

Cognitive decline often presents with overlapping neurodegenerative and vascular features, posing diagnostic and therapeutic challenges in clinical practice. This review synthesizes current evidence on the epidemiology, pathophysiology, risk factors, clinical presentation, diagnostic approach, and management of patients with mixed dementia, emphasizing case-based learning for healthcare professionals. Recent advances and guideline-based recommendations are discussed to inform practical clinical decisions and optimize patient outcomes.

Introduction

The coexistence of neurodegenerative and vascular pathology is increasingly recognized as a major contributor to cognitive impairment in the aging population. Mixed dementia, characterized by the simultaneous presence of Alzheimer's disease (AD) pathology and cerebrovascular disease, accounts for a significant proportion of dementia cases encountered in clinical practice. The complex interplay between these pathologies complicates diagnosis and management, necessitating a comprehensive, mechanism-based approach for optimal care. This article aims to provide an evidence-based, case-oriented overview of cognitive decline with mixed features, integrating recent scientific advances and clinical guidelines relevant to practicing physicians.

Epidemiology / Disease Burden

Mixed dementia is highly prevalent, especially among older adults. Autopsy studies reveal that up to 50% of dementia cases exhibit both neurodegenerative and vascular lesions. The incidence increases with age, with population-based cohorts estimating that mixed pathology may be responsible for nearly half of all dementia cases in individuals over 80 years old. The clinical burden is considerable: patients with mixed features experience more rapid progression, higher rates of hospitalization, and increased caregiver stress compared to those with pure neurodegenerative or vascular dementia. As both cardiovascular and neurodegenerative diseases rise with global aging, the prevalence and burden of mixed cognitive impairment are expected to escalate, highlighting the need for targeted strategies in prevention and care.

Pathophysiology

The pathogenesis of mixed dementia is multifactorial. Neurodegenerative processes, such as amyloid-β accumulation and tau pathology characteristic of AD, coexist with cerebrovascular injury, including microinfarcts, lacunes, white matter hyperintensities, and arteriolosclerosis. Vascular dysfunction can exacerbate neurodegeneration by impairing cerebral perfusion, promoting blood-brain barrier disruption, and facilitating the deposition of neurotoxic proteins. Conversely, neurodegenerative changes can increase vulnerability to vascular insults. Shared mechanisms such as chronic inflammation, oxidative stress, and metabolic dysregulation further drive cognitive decline. Understanding these intertwined pathways is critical for developing effective diagnostic and therapeutic interventions.

Risk Factors

Risk factors for mixed dementia reflect contributions from both neurodegenerative and vascular domains. Advanced age remains the strongest non-modifiable risk factor. Genetic predispositions, such as APOE ε4 allele, increase susceptibility to AD pathology. Traditional vascular risk factors including hypertension, diabetes mellitus, dyslipidemia, atrial fibrillation, smoking, and obesity substantially elevate the risk of cerebrovascular pathology. Lifestyle factors, physical inactivity, and midlife cardiovascular health are increasingly recognized as modifiable contributors. Chronic kidney disease and sleep disorders also play roles in promoting both vascular and neurodegenerative processes. A thorough assessment of these risk factors is essential in clinical evaluation and prevention strategies.

Clinical Features

Clinically, mixed dementia presents with a heterogeneous spectrum of cognitive and neuropsychiatric symptoms. Patients often exhibit prominent memory impairment, executive dysfunction, and slowed cognitive processing—hallmarks of both AD and vascular cognitive impairment (VCI). Additional features may include visuospatial deficits, language disturbances, and fluctuations in attention. Neurological signs such as gait abnormalities, parkinsonism, pseudobulbar affect, and focal deficits may signal vascular involvement. Neuropsychiatric symptoms, including depression, apathy, agitation, and psychosis, are frequently observed and contribute to morbidity. Case-based learning underscores the importance of recognizing mixed features to avoid misdiagnosis and to tailor management appropriately.

Diagnosis

Diagnosing mixed dementia requires a high index of suspicion and a systematic approach. Clinical history and cognitive assessment tools (e.g., MMSE, MoCA) are foundational but often insufficient for differentiation. Neuroimaging plays a pivotal role: MRI can detect hippocampal atrophy (suggestive of AD), as well as white matter changes, lacunes, and infarcts indicative of vascular injury. Advanced techniques, such as amyloid PET and tau imaging, provide molecular specificity but are not universally available. Cerebrospinal fluid biomarkers (Aβ42, tau, phosphorylated tau) aid in the identification of underlying AD pathology. Laboratory investigations should exclude reversible causes (e.g., vitamin deficiencies, thyroid dysfunction). The consensus guidelines recommend integrating clinical, neuroimaging, and biomarker data to achieve diagnostic confidence.

Treatment & Management

Management of mixed dementia is multifaceted, targeting both neurodegenerative and vascular components. Cognitive enhancers, such as cholinesterase inhibitors and memantine, offer modest symptomatic benefit and are supported by evidence in mixed cases. Vascular risk factor modification is paramount: aggressive control of hypertension, diabetes, and dyslipidemia, alongside antiplatelet therapy and smoking cessation, can slow cognitive decline and reduce recurrent cerebrovascular events. Multidisciplinary interventions including physical activity, occupational therapy, cognitive rehabilitation, and caregiver support—are essential for maintaining function and quality of life. Neuropsychiatric symptoms often require individualized pharmacologic and non-pharmacologic strategies. Regular monitoring and patient-centered care planning are key to optimizing outcomes.

Recent Advances / Emerging Therapies

Recent advances in the field include the development of novel biomarkers (e.g., plasma Aβ and tau assays) that enhance early detection of mixed pathology. Anti-amyloid monoclonal antibodies, such as aducanumab and lecanemab, have shown promise in early AD and may have a role in selected mixed cases, although vascular safety remains a concern. Ongoing trials are evaluating the efficacy of disease-modifying therapies targeting tau, neuroinflammation, and cerebral amyloid angiopathy. Advances in neuroimaging, including ultra-high-field MRI and automated volumetric analysis, improve diagnostic precision. Personalized medicine approaches, integrating genetic, biomarker, and lifestyle data, are poised to refine risk stratification and therapeutic tailoring in the near future.

Guideline Recommendations

International and national guidelines emphasize a comprehensive, multidisciplinary approach to the diagnosis and management of mixed dementia. The American Heart Association/American Stroke Association recommends routine screening for cognitive impairment in patients with vascular risk factors. The 2023 Alzheimer's Association guidelines advocate for the integration of clinical, neuroimaging, and biomarker data in diagnosis. Early intervention on modifiable vascular risks, combined with evidence-based cognitive therapies, is strongly endorsed. Caregiver education and support, advance care planning, and regular follow-up are integral components of high-quality care. Guidelines also highlight the need for ongoing research and inclusion of mixed pathology in clinical trials to advance therapeutic options.

Conclusion

Cognitive decline with mixed neurodegenerative and vascular features represents a complex and increasingly common clinical challenge. A nuanced, evidence-based approach encompassing thorough assessment, risk factor modification, symptomatic management, and emerging therapies is essential for optimizing patient outcomes. Case-based learning facilitates the integration of scientific knowledge with practical clinical skills, ensuring that healthcare professionals are equipped to deliver high-quality, individualized care in this evolving field.